Matthew Winton, Ph.D., joined Inozyme as Senior Vice President and Chief Operating Officer in April 2023. Dr. Winton most recently served as senior vice president and head of the Multiple Sclerosis franchise for Biogen’s US organization. Previously, he was the head of Spinal Muscular Atrophy (SMA) franchise in the US, where he was responsible for setting strategic direction for the infant, pediatric, and adult markets. Dr. Winton also served as Director, Payer and Channel Marketing, where he was responsible for the development and execution of pricing, access, and reimbursement strategies across various therapeutic franchises. In particular, he helped successfully prepare the organization for the approval and launch its first orphan disease drug, SPINRAZA™.
Dr. Winton began his career in management consulting, where he provided strategic and operational support to senior and executive level clients ranging from small biotech startups to large multinational pharmaceutical companies. Dr. Winton earned his Bachelor of Science in biology and psychology from York University in Toronto, Ontario, Canada. He holds a Ph.D. in neuroscience from the University of Montreal, an MBA in healthcare management from Boston University, and did a postdoctoral fellowship in neurodegenerative disease at the University of Pennsylvania.